Biomaterial design strategies for enhancing mitochondrial transplantation therapy

IF 15.5
BMEMat Pub Date : 2026-07-01 Epub Date: 2025-11-27 DOI:10.1002/bmm2.70046
Shaoyang Kang, Yushan Zhang, Hang Li, Sirui Peng, Donghao Lyu, Chunxiao Zhou, Sheng Ding, Zujian Feng, Pingsheng Huang, Chuangnian Zhang, Hongjun Wang, Deling Kong, Weiwei Wang
{"title":"Biomaterial design strategies for enhancing mitochondrial transplantation therapy","authors":"Shaoyang Kang,&nbsp;Yushan Zhang,&nbsp;Hang Li,&nbsp;Sirui Peng,&nbsp;Donghao Lyu,&nbsp;Chunxiao Zhou,&nbsp;Sheng Ding,&nbsp;Zujian Feng,&nbsp;Pingsheng Huang,&nbsp;Chuangnian Zhang,&nbsp;Hongjun Wang,&nbsp;Deling Kong,&nbsp;Weiwei Wang","doi":"10.1002/bmm2.70046","DOIUrl":null,"url":null,"abstract":"<p>Mitochondrial dysfunction is linked to various diseases, such as ischemic syndrome and type 2 diabetes, primarily due to insufficient energy supply caused by low adenosine triphosphate levels. Mitochondrial transplantation therapy is an emerging therapeutic strategy that can supplement the respiratory capacity of damaged mitochondria, thereby addressing mitochondrial disorders at their root. However, poor viability after isolation from cells, difficulties in targeting delivery in vivo, and low cellular internalization efficiency constitute the major challenges for the clinical translation of mitochondrial transplantation. The integration of advanced biomaterial design may hold the key to address these issues and improve the therapeutic efficacy of mitochondrial transplantation. In this review, we summarize recent advancements in biomaterial-assisted mitochondrial transplantation by protecting mitochondria during delivery, improving the targeting efficiency in vivo, and facilitating mitochondrial internalization. We also emphasize the importance of synergistic therapy of mitochondrial transplantation with other therapies. Finally, we discuss current issues and potential future directions of biomaterial-assisted mitochondrial transplantation therapy, aiming to further promote its clinical translation.</p>","PeriodicalId":100191,"journal":{"name":"BMEMat","volume":"4 2","pages":""},"PeriodicalIF":15.5000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bmm2.70046","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMEMat","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bmm2.70046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Mitochondrial dysfunction is linked to various diseases, such as ischemic syndrome and type 2 diabetes, primarily due to insufficient energy supply caused by low adenosine triphosphate levels. Mitochondrial transplantation therapy is an emerging therapeutic strategy that can supplement the respiratory capacity of damaged mitochondria, thereby addressing mitochondrial disorders at their root. However, poor viability after isolation from cells, difficulties in targeting delivery in vivo, and low cellular internalization efficiency constitute the major challenges for the clinical translation of mitochondrial transplantation. The integration of advanced biomaterial design may hold the key to address these issues and improve the therapeutic efficacy of mitochondrial transplantation. In this review, we summarize recent advancements in biomaterial-assisted mitochondrial transplantation by protecting mitochondria during delivery, improving the targeting efficiency in vivo, and facilitating mitochondrial internalization. We also emphasize the importance of synergistic therapy of mitochondrial transplantation with other therapies. Finally, we discuss current issues and potential future directions of biomaterial-assisted mitochondrial transplantation therapy, aiming to further promote its clinical translation.

Abstract Image

加强线粒体移植治疗的生物材料设计策略
线粒体功能障碍与各种疾病有关,如缺血性综合征和2型糖尿病,主要是由于低三磷酸腺苷水平引起的能量供应不足。线粒体移植治疗是一种新兴的治疗策略,可以补充受损线粒体的呼吸能力,从而从根本上解决线粒体疾病。然而,细胞分离后生存能力差、体内靶向递送困难、细胞内化效率低是线粒体移植临床转化的主要挑战。融合先进的生物材料设计可能是解决这些问题和提高线粒体移植治疗效果的关键。本文综述了生物材料辅助线粒体移植的最新进展,包括在分娩过程中保护线粒体、提高体内靶向效率和促进线粒体内化。我们还强调了线粒体移植与其他疗法协同治疗的重要性。最后,我们讨论了生物材料辅助线粒体移植治疗的当前问题和潜在的未来方向,旨在进一步促进其临床转化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书